Gabelli & Co. Initiates Coverage on K2M Group Holdings Inc(NASDAQ:KTWO). The shares have been rated Buy. The rating by Gabelli & Co. was issued on Sep 16, 2016.
In a different note, On Aug 4, 2016, Barclays said it Maintains its rating on K2M Group Holdings Inc. In the research note, the firm Raises the price-target to $20.00 per share. The shares have been rated ‘Overweight’ by the firm. Oppenheimer said it Initiates Coverage on K2M Group Holdings Inc, according to a research note issued on Jul 19, 2016. The shares have been rated ‘Outperform’ by the firm.
K2M Group Holdings Inc (KTWO) made into the market gainers list on Thursdays trading session with the shares advancing 3.00% or 0.51 points. Due to strong positive momentum, the stock ended at $17.52, which is also near the day’s high of $17.72. The stock began the session at $17.05 and the volume stood at 3,88,806 shares. The 52-week high of the shares is $23 and the 52 week low is $10.1. The company has a current market capitalization of $738 M and it has 4,21,45,185 shares in outstanding.
K2M Group Holdings Inc(KTWO) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $59.23M. Analysts had an estimated revenue of $57.50M. Earnings per share were $-0.27. Analysts had estimated an EPS of $-0.28.
Several Insider Transactions has been reported to the SEC. On Jul 6, 2016, Gregory S Cole (Chief Financial Officer) sold 943 shares at $15.70 per share price.Also, On May 10, 2016, George Z Moratis (Global Accounting Officer) sold 900 shares at $11.40 per share price.On May 5, 2016, Carlos A Ferrer (director) purchased 20,000 shares at $11.32 per share price, according to the Form-4 filing with the securities and exchange commission.
K2M Group Holdings Inc. (KTWO) is a global medical device company focused on designing developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies such as deformity (primarily scoliosis) trauma and tumor. The Company is engaged in the design development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s technologies include MESA Rail 4D Deformity Cricket CAPRI SERENGETI RAVINE EVEREST and tifix. The Company offers products-based on its technologies for complex spine minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.